Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1047Neoplasms 821Carcinoma, Non-Small-Cell Lung 806Prostatic Neoplasms 628Colorectal Neoplasms 536Lung Neoplasms 489Neoplasm Metastasis 439Multiple Myeloma 399Leukemia, Myeloid, Acute 392Ovarian Neoplasms 336Pancreatic Neoplasms 318Melanoma 300Squamous Cell Carcinoma of Head and Neck 269Recurrence 260Carcinoma, Hepatocellular 251Glioblastoma 241Brain Neoplasms 240Triple Negative Breast Neoplasms 214Head and Neck Neoplasms 211Carcinoma, Renal Cell 211Precursor Cell Lymphoblastic Leukemia-Lymphoma 205Lymphoma 203Stomach Neoplasms 200Endometrial Neoplasms 191Uterine Cervical Neoplasms 185Glioma 184Sarcoma 183Lymphoma, Non-Hodgkin 183Lymphoma, Large B-Cell, Diffuse 168Hematologic Neoplasms 165

Interventions

Paracentesis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Malignant Ascites × 90 days × Clear all
NCT06432296 2026-05-11

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Wuhan YZY Biopharma Co., Ltd.

Phase 3 Active not recruiting
312 enrolled

Malignant Ascites

NCT07490626 2026-03-27

Paracentesis

University of Utah

Phase NA Not yet recruiting
20 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡